Audentes Therapeutics (BOLD) Misses Q3 EPS by 1c

Audentes Therapeutics (NASDAQ: BOLD) reported Q3 EPS of ($0.74), $0.01 worse than the analyst estimate of ($0.73).

For earnings history and earnings-related data on Audentes Therapeutics (BOLD) click here.

You May Also Be Interested In

• Alphabet Sees FY26 Capex $195B To $205B, Saw $180B To $190B
• Oceaneering (OII) Tops Q2 EPS by 19c
• Kaiser Aluminum (KALU) Tops Q2 EPS by 335c